KUALA LUMPUR, Nov 22 -- Phenomics Health Inc, a bioinformatics platform-based precision medicine company has acquired the patented pharmacometabolomic technology portfolio of Precera Bioscience, based in Franklin, Tenn.
The company plans to integrate the new technology with its own patented, advanced pharmacogenomics platform to offer healthcare providers a more complete view of patients’ potential and actual response to medications than is currently available.
To be marketed under the Prec?sMed brand and licensed to clinical laboratories and healthcare systems, this patented pharmacometabolomic technology enables detection, quantitative measurement and comprehensive assessment of more than 200 medications in a patient’s bloodstream.
“Prec?sMed could help improve patient treatment outcomes, avoid adverse drug reactions and reduce patient treatment costs – the real definition of precision medicine,” said Phenomics Health co-founder, chairman and president, Dr James S. Burns.
Combined with Phenomics Health’s technology, the resulting information from Prec?sMed will help clinicians personalise drug therapy by determining what medications and dose a patient is actually taking (whether prescribed or not), drug-drug interactions and how genetics may impact the body’s ability to process those medications.
Phenomics Health also plans to use the information gathered from de-identified patient population data to inform its machine learning and AI-based bioinformatics platform, which can be mined for present and future research.
-- BERNAMA
No comments:
Post a Comment